Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018−2020)-Reference-Cited by-同舟云学术

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018−2020)

Published:2023-01 Issue:1 Volume:105 Page:115820
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Sader Helio S.^ORCID,Castanheira Mariana,Duncan Leonard R.,Mendes Rodrigo E.

Funder

AbbVie

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference15 articles.

1. Off-label use of ceftaroline fosamil: a systematic review;Pani;Int J Antimicrob Agents,2019

2. Ceftaroline fosamil for treatment of pediatric complicated skin and soft tissue infections and community-acquired pneumonia;Esposito;Paediatr Drugs,2021

3. TEFLARO®, Package Insert,2021

4. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin or vancomycin from U.S. hospitals (2008–2011);Sader;Antimicrob Agents Chemother,2013

5. Antimicrobial susceptibility trends among Staphylococcus aureus from U. S. hospitals: Results from 7 years of the ceftaroline (AWARE) surveillance program (2010-2016);Sader;Antimicrob Agents Chemother,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thiazole derivatives: prospectives and biological applications;Journal of Sulfur Chemistry;2024-04-24

2. How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice;Clinical Infectious Diseases;2024-04-04

3. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantStaphylococcus aureuspneumonia;European Respiratory Review;2023-10-18

4. Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections;Current Opinion in Infectious Diseases;2023-02-13